Through this rule, FDA is updating the standards for FDA acceptance of data from clinical investigations conducted outside the United States to help ensure the quality and integrity of data obtained from these investigations and the protection of human subjects. In this rule, FDA is amending the regulations for PMA applications, HDE applications, IDE applications, and premarket notification submissions. As part of this rule, FDA also is amending the IDE regulations and the premarket notification regulations to address the requirements for FDA acceptance of data from clinical investigations conducted inside the United States.
News & Trends
Procurar
Recentes
- EMVO Systems Updates | May 2026
- EU agrees to simplify AI rules to boost innovation and ban ‘nudification’ apps to protect citizens
- Formação DIGITAL PROMO REVIEW : ” Formação muito interativa , bem estruturada e com elevada partilha de casos práticos “
- Best Practice Guidance for the Submission of Technical Documentation under Annex II and III of Medical Device Regulation
- COMMISSION IMPLEMENTING REGULATION laying down certain uniform quality management and procedural requirements for the conformity assessment activities carried out by a notified body designated
- MASTER COURSE SUPLEMENTOS ALIMENTARES : “Evento muito bem organizado, conduzido e menistrado “
- Guidelines on the best practices for the traceability of medicines in hospital settings
- MDCG 2021-12 Rev.2 FAQ on the European Medical Device Nomenclature (EMDN) Revision 2 – April 2026

